<DOC>
	<DOCNO>NCT01207492</DOCNO>
	<brief_summary>Nilotinib drug use treat form blood cancer call leukemia . Nilotinib work block action protein might important growth pigment villonodular synovitis ( PVNS ) . In research study investigator test whether nilotinib stop growth PVNS improve symptom experienced PVNS .</brief_summary>
	<brief_title>Nilotinib Patients With Relapsed Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor</brief_title>
	<detailed_description>- In research study , cycle study drug dose last 4 week ( 28 day ) . During cycle , participant take nilotinib mouth twice daily . During first cycle , participant come clinic Days 1 8 . For Cycles 2-4 every 3 cycle thereafter , come clinic Day 1 . - The following test procedure perform specific time point study treatment : MRI CT scan ; physical examination ; vital sign ; blood work ; questionnaire EKG . - Participants may continue research study long serious side effect disease get bad .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Synovitis , Pigmented Villonodular</mesh_term>
	<criteria>Histologically confirm diagnosis recurrent PVNS ( diffusetype giant cell tumor tenosynovial giant cell tumor ) unresectable , metastatic , patient refuse surgical intervention Progressive disease last 12 month , demonstrate image clinical appearance new tumor , opinion treat investigator At least one site measurable disease accord RECIST 1.1 MRI ( CT scan metastatic disease ) Any number type prior systemic therapy , exception know suspected CSF1 receptor inhibitor outline exclusion criterion 18 year age old Life expectancy great 6 month ECOG Performance Status 0 , 1 2 Normal organ marrow function define protocol QTc le equal 450 m 12lead ECG Negative urine serum pregnancy test within day start study drug administration woman childbearing potential . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation , 3 month follow study drug discontinuation Prior treatment know suspected CSF1 receptor inhibitor , include nilotinib , imatinib , sunitinib , sorafenib , approve investigational tyrosine kinase inhibitor use treatment diffusetype giant cell tumor Concurrent treatment investigational agent Inability tolerate contraindication MRI scan participant localized disease Impaired cardiac function Current treatment strong CYP3A4 inhibitor either discontinue switched different medication prior start study drug Current treatment medication potential prolong QT interval either discontinue switched different medication prior start study drug Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug Acute chronic pancreatic disease Acute chronic liver disease Another primary malignant disease require systemic treatment radiation History significant congenital acquire bleed disorder unrelated cancer Major surgery within 28 day prior Day 1 study Treatment investigational agent within 28 day day 1 History noncompliance medical regimen inability grant consent Women pregnant breastfeed Other comorbidities would interfere study participation safety opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nilotinib</keyword>
</DOC>